<DOC>
	<DOCNO>NCT02154113</DOCNO>
	<brief_summary>The purpose study compare clinical performance Ultrashape system VelaShape II device reduction waist .</brief_summary>
	<brief_title>Ultrashape System Combination With VelaShape II Device Circumferential Reduction</brief_title>
	<detailed_description>UltraShape® Contour I V3 system non-invasive ( break skin ) focus ultrasound body contour purposesdesigned selectively disrupt sub-dermal fat cell employ focused ultrasound . All type tissue , blood vessel , muscle peripheral nerve , remain intact . There thermal effect . Fat-cell destruction achieve ultrasound-induced mechanical effect short exposure time . VelaShape non-invasive device Body Reshaping Cellulite Treatment . VelaShape combine control infrared ( IR ) light conduct bipolar radiofrequency ( RF ) energies mechanical manipulation .</detailed_description>
	<criteria>1 . Fat thickness least 1.5 cm anterior abdominal flank prior initial treatment ( measurement caliper ) 2 . For woman childbearing potential : negative pregnancy test 24 hour period prior enrollment 24 hour period prior treatment FU visit ( measure urine ) 3 . General good health confirm medical history skin examination treat area 4 . Written inform consent participate study 5 . Ability comply requirement study 6 . BMI≤ 30 1 . History hypertension , ischemic heart disease , valvular heart disease , congestive heart failure , pacemaker/defibrillator , abdominal aortic aneurism 2 . Current hyperlipidemia , diabetes mellitus , hepatitis , liver disease , HIV positive status , blood coagulopathy excessive bleeding , autoimmune connective tissue disease malignancy 3 . Previous liposuction treatment area 4 . History skin disease treatment area , know tendency form keloid poor wound heal 5 . Skin lesion treatment area simple nevi physical examination ( e.g. , atypical nevus , tattoo , abrasion ) include depressed scar treatment area 6 . Poor skin quality ( i.e. , laxity ) 7 . Abdominal wall diastasis hernia physical examination 8 . Abnormal kidney , liver coagulation function , abnormal lipid profile blood count within last 3 month 9 . Obesity ( BMI &gt; 30 ) 10 . Childbirth within last 12 month woman suckle child 11 . Any acute chronic condition , opinion Investigator , could interfere conduct study 12 . Unstable weight within last 6 month ( i.e. , ± 3 % weight change prior six month ) 13 . Inability comply circumference measurement procedure ( e.g. , inability hold breath require duration ) 14 . Participation another clinical study 15 . Previous body contour treatment treatment area</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Syneron</keyword>
	<keyword>Velashape</keyword>
	<keyword>ELOS</keyword>
	<keyword>Ultrashape</keyword>
</DOC>